Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.
Top comments
The DeviceTalks Podcast Network is the ultimate destination for all things #MedTech. By subscribing to this single feed, you’ll gain access to every podcast in our diverse and growing portfolio—more than a dozen unique shows featuring senior leaders, groundbreaking technology insights, and in-depth discussions on the most important topics in the medical device industry.
Each episode dives deep into critical areas like business strategy, market trends, surgical robotics, orthopedics, structural heart, neurology, and beyond. You’ll hear from leading voices at top companies—ranging from major OEMs to innovative startups—sharing their solutions, stories, and strategies for tackling the indust...